EVO vs. BBIO, OGN, IONS, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Evotec (NASDAQ:EVO) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
Evotec has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Evotec has higher revenue and earnings than BridgeBio Pharma.
In the previous week, BridgeBio Pharma had 7 more articles in the media than Evotec. MarketBeat recorded 18 mentions for BridgeBio Pharma and 11 mentions for Evotec. Evotec's average media sentiment score of 0.79 beat BridgeBio Pharma's score of 0.47 indicating that Evotec is being referred to more favorably in the media.
BridgeBio Pharma received 140 more outperform votes than Evotec when rated by MarketBeat users. However, 80.00% of users gave Evotec an outperform vote while only 68.25% of users gave BridgeBio Pharma an outperform vote.
5.8% of Evotec shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 1.0% of Evotec shares are owned by insiders. Comparatively, 24.7% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Evotec has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -246.24%.
Evotec currently has a consensus target price of $11.00, indicating a potential upside of 135.04%. BridgeBio Pharma has a consensus target price of $47.62, indicating a potential upside of 69.99%. Given Evotec's stronger consensus rating and higher possible upside, analysts plainly believe Evotec is more favorable than BridgeBio Pharma.
Summary
Evotec beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.
Get Evotec News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
